Evolus Inc
Change company Symbol lookup
Select an option...
EOLS Evolus Inc
BAC Bank of America Corp
CLOV Clover Health Investments Corp
HRL Hormel Foods Corp
DD Dupont De Nemours Inc
PSRU Valiant Eagle Inc
CRM Salesforce.Com Inc
VLYPP Valley National Bancorp
FEMKX Fidelity® Emerging Markets Fund
XPEV Xpeng Inc
Go

Health Care : Pharmaceuticals | Small Cap Growth
Company profile

Evolus, Inc. is a medical aesthetics company. The Company is focused on providing physicians and aesthetic procedures and treatments. It also focuses on offering the self-pay aesthetic market and its product candidate, PrabotulinumtoxinA (DWP-450), is an injectable 900 kilodalton, or kDa, botulinum toxin type designed to address the needs of the large and growing facial aesthetics market. It offers physicians and patients a compelling value proposition with DWP-450. OnabotulinumtoxinA (BOTOX) is the neurotoxin approved 900 kDa botulinum toxin type A complex in the United States.

Postmarket

Last Trade
Delayed
$14.27
0.25 (1.78%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$14.02
Day's Change
1.51 (12.07%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
14.50
Day's Low
12.83
Volume
(Light)
Volume:
1,496,068

10-day average volume:
4,533,404
1,496,068

Display:

Providers:

UpdateCancel
All providers
Today's News, March 02, 2021
Evolus to Participate in Two Upcoming Investor Conferences

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that members of management will be participating in two upcoming virtual investor conferences. (Globe Newswire)

February 26, 2021
Evolus Announces Promotion of Crystal Muilenburg to Chief Marketing Officer

Evolus, Inc. (Nasdaq: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced the promotion of Crystal Muilenburg from VP, Corporate Communications & PR to Chief...(Globe Newswire)

February 24, 2021
Evolus downgraded to hold from buy at Truist

(END) Dow Jones Newswires February 24, 2021 07:43 ET (12:43 GMT) (MarketWatch)

February 23, 2021
Evolus Announces Preliminary, Unaudited, Fourth Quarter and Full Year 2020 Net Revenue

Evolus, Inc. (NASDAQ: EOLS) today announced its preliminary, unaudited, net revenues for the fourth quarter and full year ended December 31, 2020. The preliminary unaudited results described in this press release are estimates only and are subject...(Globe Newswire)

February 22, 2021
Evolus to Participate in the 10th Annual SVB Leerink Global Healthcare Conference

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that members of management will be participating in the 10 Annual SVB Leerink Global Healthcare...(Globe Newswire)

Evolus stock price target raised to $9 from $5 at Mizuho

(END) Dow Jones Newswires February 22, 2021 06:52 ET (11:52 GMT) (MarketWatch)

February 19, 2021
AbbVie, Evolus, and Medytox Announce Resolution of Intellectual Property Litigation

AbbVie (NYSE: ABBV), Evolus (NASDAQ: EOLS) and Medytox announce settlement agreements to fully resolve all outstanding litigation, including the United States International Trade Commission (ITC) case regarding the sale of Jeuveau(R), between the...(PR Newswire)

February 16, 2021
Botulinum Toxin Market Size Worth USD 9442.93 Million by 2025 at 10.3% CAGR | Growing Demand for Non-Invasive Cosmetic Procedures to Boost Global Industry, Says Market Research Future (MRFR)

Global Botulinum Toxin Market Overview: Market Research Future (MRFR) projects the Botulinum Toxin Market value to reach USD 9442.93 Million by 2025 while expanding at a CAGR of 10.3%, predicts Market Research Future (MRFR). (Globe Newswire)

December 17, 2020
Thinking about buying stock in Evolus, Rite Aid, Roku, Marathon Patent Group, or Otonomy?

InvestorsObserver issues critical PriceWatch Alerts for EOLS, RAD, ROKU, MARA, and OTIC. https://mma.prnewswire.com/media/1333368/InvestorsObserver_Logo.jpg To see how InvestorsObserver's proprietary scoring system rates these stocks, view the...(PR Newswire)

December 16, 2020
Evolus Provides Update on United States International Trade Commission (ITC) Case

Section 337 Violation Partially Affirmed by ITC JeuveauSales and Marketing Continue Under Bond All Options Under Review to Resolve Legal Dispute Evolus, Inc. (NASDAQ: EOLS) today announced that the United States International Trade Commission (ITC)...(Globe Newswire)

December 15, 2020
EOLS Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Evolus, Inc. Shareholders of Class Action and Lead Plaintiff Deadline: December 15, 2020

New York, New York--(Newsfile Corp. - December 15, 2020) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Evolus, Inc. (NASDAQ: EOLS) ("Evolus" or "the Company") and certain of its...(Newsfile)

EOLS FINAL DEADLINE TODAY: ROSEN, NATIONAL TRIAL LAWYERS, Reminds Evolus, Inc. Investors of Important December 15 Deadline in Securities Class Action - EOLS

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Evolus, Inc. (NASDAQ: EOLS) between February 1, 2019 and July 6, 2020, inclusive (the "Class Period"), of the important December 15, 2020 lead plaintiff...(Globe Newswire)

December 14, 2020
Evolus Deadline Alert

New York, New York--(Newsfile Corp. - December 14, 2020) -  If you suffered losses exceeding $250,000 investing in Evolus stock or options between February 1, 2019 and July 6, 2020 and would like to discuss your legal rights, click...(Newsfile)

Evolus, Inc. Investors: Last Days to Participate Actively in the Class Action Lawsuit; Portnoy Law

The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of Evolus, Inc. (NASDAQ:EOLS) investors that acquired shares between February 1, 2019 and July 6, 2020. Investors have until December 15, 2020 to seek an...(Globe Newswire)

DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Evolus, Inc. and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that a class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of investors that...(Globe Newswire)

DEADLINE REMINDER: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Evolus, Inc. (EOLS)

Law Offices of Howard G. Smith reminds investors of the upcoming December 15, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Evolus, Inc.("Evolus" or the "Company") (NASDAQ: EOLS)...(PR Newswire)

DEADLINE TUESDAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Evolus, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Los Angeles, California--(Newsfile Corp. - December 14, 2020) -  The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Evolus, Inc. ("Evolus" or "the Company") (NASDAQ: EOLS) for...(Newsfile)

EOLS Final Deadline Tomorrow: Rosen, A Global and Leading Law Firm, Reminds Evolus, Inc. Investors of Important December 15 Deadline in Securities Class Action - EOLS

New York, New York--(Newsfile Corp. - December 14, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Evolus, Inc. (NASDAQ: EOLS) between February 1, 2019 and July 6, 2020, inclusive (the "Class...(Newsfile)

Evolus, Inc. Investors: Last Days to Participate Actively in the Class Action Lawsuit; Portnoy Law

The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of Evolus, Inc. (NASDAQ:EOLS) investors that acquired shares between February 1, 2019 and July 6, 2020. Investors have until December 15, 2020 to seek an...(Globe Newswire)

December 13, 2020
Evolus Shareholder Alert

New York, New York--(Newsfile Corp. - December 13, 2020) - If you suffered losses exceeding $250,000 investing in Evolus stock or options between February 1, 2019 and July 6, 2020 and would like to discuss your legal rights, click...(Newsfile)

Next >

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.